Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CDC Loses Faith In AstraZeneca's Nasal Spray Flu Vaccine

Executive Summary

The US Centers for Disease Control and Prevention has decided not to recommend AstraZeneca PLC's nasal spray flu vaccine FluMist Quadrivalent (known as Fluenz Tetra in Europe) for the upcoming flu season owing to lack of efficacy. AstraZeneca said it would take an $80m write-down on stocks in the second quarter as a result.


Related Content

Europe Set To Get Live Pandemic Bird Flu Vaccine Protection


Related Companies